Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-cancer Drugs Associated Atrial Fibrillation—An Analysis of Real-World Pharmacovigilance Data
Javaria Ahmad, Aswani Thurlapati, Sahith Reddy Thotamgari, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 23

Showing 23 citing articles:

Updated insights on dementia‐related risk of sacubitril/valsartan: A real‐world pharmacovigilance analysis
Congqin Chen, Lingqing Ding, Fang Fu, et al.
CNS Neuroscience & Therapeutics (2023) Vol. 29, Iss. 9, pp. 2548-2554
Open Access | Times Cited: 26
Atrial fibrillation, cancer and anticancer drugs
Jonaz Font, Paul Milliez, Alexandre-Boudjema Ouazar, et al.
Archives of cardiovascular diseases (2023) Vol. 116, Iss. 4, pp. 219-226
Open Access | Times Cited: 14
Drug-induced atrial fibrillation. A narrative review of a forgotten adverse effect
Juan Tamargo, Julián Pérez‐Villacastín, Ricardo Caballero, et al.
Pharmacological Research (2024) Vol. 200, pp. 107077-107077
Open Access | Times Cited: 6
Advancing drug development for atrial fibrillation by prioritising findings from human genetic association studies
Kishore Kukendrarajah, Aliki-Eleni Farmaki, Pier D. Lambiase, et al.
EBioMedicine (2024) Vol. 105, pp. 105194-105194
Open Access | Times Cited: 4
Risk of drug-induced angioedema: a pharmacovigilance study of FDA adverse event reporting system database
Maoxia Fan, Kaibin Niu, Xiaoqi Wu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Ibrutinib and Bruton’s Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac Death
Giuseppe Boriani, Pierantonio Menna, Riccardo Morgagni, et al.
Chemotherapy (2022) Vol. 68, Iss. 2, pp. 61-72
Open Access | Times Cited: 19
Clinical evaluation and outcome in heart failure patients receiving chemotherapy with different anti‐cancer agents
Tomiko Sunaga, Takahiro Okada, Yoshitaka Iso, et al.
ESC Heart Failure (2025)
Open Access
Mechanisms and Management of Arrhythmias in Cancer Patients
Manyoo Agarwal, Aadhavi Sridharan, Hoang Nhat Pham, et al.
Current Treatment Options in Cardiovascular Medicine (2025) Vol. 27, Iss. 1
Closed Access
Safety of catheter ablation for atrial fibrillation in patients with cancer: a nationwide cohort study
Sahith Reddy Thotamgari, Aakash Sheth, Harsh Patel, et al.
Postgraduate Medicine (2023) Vol. 135, Iss. 6, pp. 562-568
Closed Access | Times Cited: 9
Cardiac Arrhythmias in Oncological Patients—Epidemiology, Risk Factors, and Management within the Context of the New ESC 2022 Guidelines
Michał Gawlik, Jakub Michał Zimodro, Aleksandra Gąsecka, et al.
Current Oncology Reports (2023) Vol. 25, Iss. 10, pp. 1107-1115
Open Access | Times Cited: 9
Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system
Dehua Zhao, Xiaoqing Long, Jisheng Wang
BMC Pharmacology and Toxicology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 3
Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms
Adnan Shaaban, Shane S. Scott, Ashley Greenlee, et al.
Journal of Molecular and Cellular Cardiology (2024) Vol. 194, pp. 118-132
Open Access | Times Cited: 3
Cardiotoxicity in Acute Myeloid Leukemia in Adults: A Scoping Study
Ioannis Konstantinidis, Sophia Tsokkou, Savas Grigoriadis, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2474-2474
Open Access | Times Cited: 3
Recent Advance in the biological activity of synephrine in Citri Reticulatae Pericarpium
Yuechang Huang, Jiamin Li, Baizhong Chen, et al.
European Journal of Medicinal Chemistry Reports (2022) Vol. 5, pp. 100061-100061
Open Access | Times Cited: 12
Risk of atrial fibrillation in patients with multiple myeloma: what is known and directions for future study
Ting Fu, Yuxiao Chen, Lian Lou, et al.
The Egyptian Heart Journal (2024) Vol. 76, Iss. 1
Open Access | Times Cited: 2
Arrhythmias in oncological patients: a compact overview for the clinician
Konstantinos Iliodromitis, Mathias Hoiczyk, Nana‐Yaw Bimpong‐Buta, et al.
Herzschrittmachertherapie + Elektrophysiologie (2024) Vol. 35, Iss. 3, pp. 177-182
Closed Access | Times Cited: 1
Trends in Cardiovascular Mortality in Patients With Atrial Fibrillation and Cancer in the United States (1999 to 2020)
Aakash Sheth, Udhayvir Singh Grewal, Sahith Reddy Thotamgari, et al.
The American Journal of Cardiology (2023) Vol. 205, pp. 162-163
Open Access | Times Cited: 2
Remote electrocardiogram monitoring in cancer patients for detecting cardiotoxicity. Case report
D. F. Mesitskaya, Anastasia S. Yasneva, Z. Z.A. Fashafsha, et al.
Terapevticheskii arkhiv (2024) Vol. 96, Iss. 4, pp. 386-390
Open Access
Atrial Fibrillation and Cancer—Epidemiology, Mechanisms, and Management
Nathaniel E. Davis, Narut Prasitlumkum, Nicholas Y. Tan
Journal of Clinical Medicine (2024) Vol. 13, Iss. 24, pp. 7753-7753
Open Access
Atrial Fibrillation in Patients with Breast Cancer: A Literature Review
Mozidat Olamide Bello, Mark Wadid, Aishwarya Malode, et al.
Cardiology and Therapy (2024)
Open Access
Atrial Fibrillation With Modern Cancer Treatment
Daniel Addison, Cooper Quartermaine, Jonathan E. Brammer
JACC CardioOncology (2023) Vol. 5, Iss. 2, pp. 227-229
Open Access
Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: A safety analysis of the FDA Adverse Event Reporting System
Dehua Zhao, Xiaoqing Long, Jisheng Wang
Research Square (Research Square) (2023)
Open Access
Cardiovascular side effects of signaling pathway inhibitors in chronic lymphocytic leukemia therapy
Peter Turcsányi, Eva Kriegová, Tomáš Papajík
Onkologie (2023) Vol. 17, Iss. 5, pp. 357-362
Closed Access
Page 1

Scroll to top